The combination of atezolizumab, cobimetinib, and vemurafenib reduced the risk of disease progression or death compared with placebo in patients with BRAF V600 mutation-positive advanced melanoma, meeting the primary endpoint of progression-free survival in the phase III IMspire150 study, according to a press release from Roche.
Evan Y. Yu, MD, discusses how adding chemotherapy to a doublet regimen for metastatic hormone-sensitive prostate cancer may be considered on an as-needed basis, particularly…
Tislelizumab combined with irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin proved effective with manageable safety as frontline therapy for advanced HER2-negative, mismatch repair–proficient gastric and GEJ adenocarcinoma…
Patients with appendiceal adenocarcinoma face increased risk of secondary cancers, including colorectal, within 10 years, per 2025 ASCO GI findings.
David M. Waterhouse, MD, MPH, and Molly Mendenhall, MBOE, LSSBB, BSN, RN, discuss how the implementation of Lean Six Sigma methodology at Oncology Hematology Care…
The FDA has granted breakthrough therapy designation to the DCISionRT test, a tool that assesses radiation therapy benefit for women aged 30 to 85 with…
Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving efficacy, minimizing adverse events, and paving the way for advanced…
The panelist discusses how the treatment landscape for early-stage relapsed/refractory multiple myeloma (R/R MM) has evolved significantly with CAR T-cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel…
Trastuzumab with chemotherapy showed numerical improvements in overall survival and progression-free survival in HER2-positive gastric and gastroesophageal junction cancers.
TACE with camrelizumab and rivoceranib significantly improves PFS in unresectable HCC, per phase 2 CARES-005 study results.
James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line…
